On June 2, 2020, Dr. Hao Hong, Chairman and CEO, Ms. Rui Yang, COO, Mr. Da Zhang, CFO and other company leaders visited Zhenjiang Economic-Technological Development Area (ZEDA) in Jiangsu Province. The group met, discussed, and reached a cooperative agreement with Mr. Minglong Ma, Secretary of Zhenjiang Municipal Party Committee, Mr. Shuhai Xu, Deputy Secretary of Zhenjiang Municipal Party Committee, Mr. Haitao Qin, Member of Zhenjiang Municipal Standing Party Committee & Secretary of ZEDA Party Committee, Mr. Jian Guo, Secretary General of Zhenjiang Municipal Party Committee, Mr. Feng Xue, Director of ZEDA Management Committee and other relevant leaders. This cooperation is expected to further accelerate Asymchem’s layout of whole industry chain service of innovative drugs and to make greater contributions to the global industry.
The booming global pharmaceutical industry has created a need for more growth of services. According to the Pharmaprojects database, there were 15,048 new drugs (preclinical, clinical phase I/II/III) in development worldwide by the end of 2019. Subsequently, the global CMO/CDMO market is expected to grow at a rate of 13.03%, reaching US$102.5 billion by 2021. As a leading CDMO company, Asymchem seized the business opportunity. The cooperation with ZEDA will be beneficial to the continuous growth of the innovative drug market and the listed dividends.
On June 2, Mr. Minglong Ma and other government leaders reached a cooperative agreement with Asymchem, represented by Dr. Hao Hong, Chairman and CEO, Ms. Rui Yang, COO, Mr. Da Zhang, CFO and other senior executives. They agreed to propose a strategic layout of the Yangtze River Delta region, and to increase the discussion about relevant cooperation matters. With the agreement reached, it is expected to speed up the second venture process of Asymchem, promoting the scale and service level of company’s R&D and production.Dr. Hao Hong commented, "Many thanks to Zhenjiang Municipal Party Committee for all the great support. With the consensus of cooperation and the consistent efficiency of Asymchem, we are expecting the quick landing of this project, and to further enhance our capability in the whole industry chain of innovative drugs.” Mr. Minglong Ma said, “I am very appreciative of Asymchem’s global leading technology and advanced management model. Zhenjiang attaches great importance to the biomedical and health industry and hopes to promote its development in the Yangtze River Delta region through resource sharing and mutual benefit with Asymchem.” In addition, Mr. Haitao Qin expressed the hope that through this cooperation, Zhenjiang can quicken its own development and bring ZEDA health industry to a brand new level.Building on Asymchem’s existing strength in the small molecule business, we have been expanding our project pipeline and growing business through our forward-looking technology investments and evolving platforms. The agreement reached may be another milestone in Asymchem's strategy to further enhance our one-stop comprehensive service capability, improve the multi-dimensional layout and accelerate the construction of an integrated service ecosphere for innovative medicines.
Today, life, medicine and health have become top priorities that countries around the world must give special attention to, especially since the outbreak of COVID-19. As a CDMO, for over 20 years and relying on the industry-leading advantages and platforms, Asymchem provides services to international and domestic markets and continuously expands its strategic layout, making greater contributions to the global biopharmaceutical industry!